CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...